期刊文献+

奥沙利铂与氟尿嘧啶及亚叶酸钙联合治疗晚期大肠癌 被引量:4

Observation on Oxaliplatin Combined with Fluorouracil and Calcium Folinate in the Treatment of 40 Cases of Advanced Colorectal Cancer
下载PDF
导出
摘要 目的 :研究奥沙利铂 (L OHP)与氟尿嘧啶 (5 FU)及亚叶酸钙 (CF)联合应用治疗晚期大肠癌的疗效和毒副反应。方法 :采用L OHP 130mg/m2 ,静脉滴入 2h ,d1;CF 2 0 0mg/m2 ,静脉滴入 2h ,d1~d5;5 FU 30 0mg/m2 (≤ 5 0 0mg/d) ,静脉滴入 4h ,d1~d5(CF滴完后 ) ;2 1d为 1个周期。结果 :总有效率为30 % ,毒副反应以骨髓抑制、感觉神经毒性为主 ,白细胞下降发生率为 4 5 % ,神经毒性发生率 80 % ,本组无Ⅳ度毒副反应。结论 :L OHP、5 FU、CF联合应用治疗晚期大肠癌疗效肯定 。 Objective To study the response and toxicity of the regimen of oxaliplatin combined with fluorouracil and calcium folinate in the treatment of advanced colorectal cancer.Methods:The regimen was oxaliplatin 130 mg/m 2 hours iv drip on the 1st day,calcium folinate 200 mg/m 2 iv drip 2 hours on days the 1st to 5 th ,followed by fluorouracil 300 mg/m 2(≤500 mg/d) iv drip 4 hours on the 1st to the 5 th ,and 21 days as one cycle.Results:The total response rate was 30%,the main toxicity was bone marrow suppression and neuro sensory toxicity.Leukopenia was observed in 45% of the patients,neuro sensory toxicity was observed in 80%.There was no toxicity and side effect of grade Ⅳ in these patients.Conclusions The regimen of oxaliplatin combined with fluorouracil and calcium folinate is effective and tolerable in advanced colorectal cancer therapy.
出处 《肿瘤防治杂志》 2003年第10期1080-1081,共2页 China Journal of Cancer Prevention and Treatment
关键词 结肠直肠肿瘤 药物疗法 有机铂化合物 投药和剂量 氟尿嘧啶 投药和剂量 叶醛酸 投药和剂量 药物疗法 联合 colorectal neoplasms/drug therapy organoplatinum compounds/administration & dosage fluorouracil/administration & dosage leucororin/administration & dosage drug therapy,combination
  • 相关文献

参考文献1

二级参考文献2

共引文献343

同被引文献27

  • 1张文,许立功.晚期结直肠癌的化疗进展[J].中国癌症杂志,2004,14(4):378-382. 被引量:25
  • 2陆仰东.国产奥沙利铂为主的联合化疗治疗51例晚期大肠癌疗效观察[J].中国肿瘤临床,2004,31(24):1401-1403. 被引量:5
  • 3李苏宜,刘琳,顾小怡,姜藻,王彩莲,董丽钧,万建平.草酸铂联合氟尿嘧啶、醛氢叶酸治疗晚期结直肠癌的临床观察[J].临床肿瘤学杂志,2006,11(8):612-614. 被引量:8
  • 4Goldstein D, Mitchell P, Michal M, et al. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer Patients[J]. Br J Cancer,2005, 92(5) :832-837.
  • 5Hsuen Lim E, Seng Cheong Lim R, Seng Wu T, et al. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma:an asian experience[J]. Pann Pharmacother,2003,37(12) :1909-1912.
  • 6Kemeny N, Garay C A, Gurtler J, et al. Randomized multicenter phase Ⅱ trial of bolus plus in FU sional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer [J]. J Clin Oncol,2005,23(1) :248-252.
  • 7Parkin D M, Bray F, Ferlay J, et al. Global cancer statistics,2002[J]. CA Cancer J Clin, 2005, 55(2) :74-108.
  • 8Rixe O, Ortuzar W,Alvarez M, et al. Oxaliplatin,tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug resistant celllines and in the cell lines of the National Cancer Institute ' s Anticancer Drug Screen panel[J]. Biochem Pharmacol, 1996,52 (12): 1855 -1865.
  • 9Kuebler J P,de Gramont A. Recent Experience With Oxaliplatin or lrinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer[J]. Semin Oncol,2004,30(4 Suppl 15) :40-47.
  • 10Simpson D, Dunn C, Curran M. Oxaliplatin: a review of its use in combination therapy for advanced metastatic colorectal cancer [J]. Drugs, 2003,63(19) :2127-2156.

引证文献4

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部